PHAT News and Press, Phathom Pharmaceuticals Inc. From 04/04/23

2023-04-04 09:38:49 ET Phathom Pharmaceuticals ( NASDAQ: PHAT ) stock rose ~10% on Tuesday after the company said it expects to refile an application seeking approval of vonoprazan to treat erosive esophagitis in Q2 2023 following a meeting with the U.S. FDA. In Februa...

Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned resubmission of erosive esophagitis new drug application (NDA) this quarter Combined commercial launch of vonoprazan for erosive esophagitis and H. pylori indications expected Q4 2...

Phathom Pharmaceuticals press release ( NASDAQ: PHAT ): Q4 GAAP EPS of -$1.33 beats by $0.01 . As of December 31, 2022, cash and cash equivalents were $155.4 million. An additional $100 million is available under Phathom’s term loan with Hercules Capital. For furt...

Meeting scheduled in March 2023 with the U.S. Food and Drug Administration (FDA) to discuss stability data and resubmission requirements for erosive GERD and H. pylori New Drug Applications FLORHAM PARK, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT...

Phathom Pharmaceuticals ( NASDAQ: PHAT ) said it has received correspondence from the US FDA formally asking for additional stability data from the company's vonoprazan products. The data is to assure the agency that levels of a nitrosamine impurity, N-nitroso-vonoprazan (NVP),&#...

FLORHAM PARK, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced regulatory updates for its approved products, VOQUEZNA™ ...

NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Credit Acceptance Corporation (NASDAQ: CACC), and Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT). Our investigations concern wh...

Shares of Phathom Pharmaceuticals (NASDAQ: PHAT) were up 44.6% this past week, according to data provided by S&P Global Market Intelligence . The stock closed last Friday at $8.61, then closed at $12.36 on Friday. Despite the rise, the stock is down nearly 40% from its 52-week hig...

Phathom Pharmaceuticals ( NASDAQ: PHAT ), which is up 5% Thursday afternoon, is continuing an upward trend that began on Jan. 20. Since market close on Jan. 19 through afternoon trading on Thursday, shares are up ~34% . BMO Capital Markets' Gary Nachman, who has an outperf...

Phathom Pharmaceuticals ( NASDAQ: PHAT ), a biopharma focused on GIT disorders, traded higher on Monday after the company said a Phase 3 trial for its experimental heartburn therapy vonoprazan met the primary endpoint. Vonoprazan is designed to block acid secretion in the stomach. The...